Pharmaceutical Jieankang-B issued an announcement on the Hong Kong Stock Exchange stating that tengotinib tablets have been approved by the Drug Evaluation Center of the China National Drug Administration to be included in the list of priority review varieties. The proposed indications are: for the treatment of adult patients with advanced, metastatic, or inoperable cholangiocarcinoma who have received at least one systematic treatment and treatment with FGFR inhibitors in the past.

Pharmaceutical Jieankang-B issued an announcement on the Hong Kong Stock Exchange stating that tengotinib tablets have been approved by the Drug Evaluation Center of the China National Drug Administration to be included in the list of priority review varieties. The proposed indications are: for the treatment of adult patients with advanced, metastatic, or inoperable cholangiocarcinoma who have received at least one systematic treatment and treatment with FGFR inhibitors in the past.